Compare Exelixis Inc. Common Stock (EXEL) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Immunovant Inc. Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $59.77 (market cap $14.62B), while Immunovant Inc. Common Stock trades at $30.5 (market cap $6.25B). The key difference: Exelixis Inc. Common Stock is far larger — about 2.3× Immunovant Inc. Common Stock's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 1 Days and Immunovant Inc. Common Stock for 1 Days on average.
| EXEL | IMVT | |
|---|---|---|
Market Cap | $14.62B | $6.25B |
Volume | 2,684,957 | 1,755,411 |
Sector | Health | Health |
52-Week High | $59.13 | $44.96 |
52-Week Low | $34.54 | $17.03 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $13.95B | $5.35B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
